The Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis in Real-world Practice in Thailand
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 09 Dec 2022 New trial record
- 09 Nov 2022 Results presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research